z-logo
open-access-imgOpen Access
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
Author(s) -
Huiyu Li,
Zhida Liu,
Longchao Liu,
Hongyi Zhang,
Chuanhui Han,
Luc Girard,
Hyunsil Park,
Anli Zhang,
Chunbo Dong,
Jianfeng Ye,
Austin Rayford,
Michael Peyton,
Xiaoguang Li,
Kimberley Avila,
Xuezhi Cao,
Shuiqing Hu,
Md Maksudul Alam,
Esra A. Akbay,
Luisa M. Solis,
Carmen Behrens,
Sharia Hernández-Ruiz,
Wei Lü,
Ignacio I. Wistuba,
John V. Heymach,
Michael Chisamore,
David Micklem,
Hani Gabra,
Gro Gausdal,
James B. Lorens,
Bo Li,
YangXin Fu,
John D. Minna,
Rolf A. Brekken
Publication year - 2022
Publication title -
cell reports medicine
Language(s) - English
Resource type - Journals
ISSN - 2666-3791
DOI - 10.1016/j.xcrm.2022.100554
Subject(s) - stk11 , cancer research , immune checkpoint , cd8 , kras , mutant , cytotoxic t cell , blockade , pembrolizumab , immunotherapy , cancer , immune system , biology , medicine , immunology , in vitro , receptor , gene , colorectal cancer , biochemistry

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom